Answers are grounded in this paper and cite their sources.
The aim of this study was to assess the efficacy of hemostatic radiotherapy (HRT) in patients with advanced cancer.Eighteen patients with advanced cancer treated with HRT at the Fukuoka University and Kyushu Rosai Hospitals in Japan between July 2010 and February 2015 were retrospectively assessed.The hemostatic effect of tumor-related bleeding was assessed by the clinical course of bleeding, laboratory data, the endoscopic study, and the number of blood transfusion units (BTRUs) for one month before and after HRT.The median follow-up time was 2.6 months (range, 0.7 to 36.2 months).The median age of the patients was 77 years (range, 51 to 93).The primary diseases with tumor-related bleeding included gastric cancer, urinary bladder cancer, gynecological cancer, prostate cancer, non-small-cell lung cancer, and breast cancer.The median overall survival time was three months, and the one year survival rate was 22.9% of all patients.The HRT regimens ranged from 30 Gy in 10 fractions to 40 Gy in 20 fractions.In all patients, the anemia grade and the number of BTRUs decreased for 1 month after RT.The percentage of patients who were diagnosed as "successful" for hemostasis was 83% (15 of 18 patients).HRT is therefore strongly suggested as effective for the control of tumor-related bleeding in patients with advanced cancer.The optimal radiation doses and fractions are controversial; however, this treatment should be offered for patients with a poor life expectancy.
No takes yet. Share an insight, caveat, or question.
Nomoto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: